(Q47771380)

5 February 2018

title

Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study (English)

1 reference

5 February 2018

1 reference

1

1 reference

5 February 2018

Kristel Van Steen

Kristel Van Steen

5

0 references

Gert Van Assche

3

Gert Van Assche

1 reference

5 February 2018

9

Paul Rutgeerts

1 reference

5 February 2018

2

Maja Noman

1 reference

5 February 2018

Sofie Joossens

7

Sofie Joossens

1 reference

5 February 2018

Xavier Bossuyt

8

Xavier Bossuyt

1 reference

5 February 2018

Filip J Baert

4

Filip Baert

1 reference

5 February 2018

Nele Esters

6

Nele Esters

1 reference

5 February 2018

language of work or name

English

0 references

publication date

1 July 2003

1 reference

5 February 2018

published in

Gastroenterology

1 reference

5 February 2018

volume

125

1 reference

5 February 2018

issue

1

1 reference

5 February 2018

page(s)

32-39

1 reference

5 February 2018

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900701-7

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900701-7

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900701-7

Infliximab for the treatment of fistulas in patients with Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900701-7

Review article: safety of infliximab in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900701-7

Long term safety of infliximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900701-7

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900701-7

D-penicillamine-induced lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900701-7

Systemic lupus erythematosus during penicillamine therapy for rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900701-7

Autoantibodies to leucocyte antigens in hydralazine‐associated nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900701-7

Musculoskeletal and systemic reactions to biological therapeutic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900701-7

Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900701-7

Low-titre auto-antibodies predict autoimmune disease during interferon-alpha treatment of chronic hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900701-7

Appearance of anti-DNA antibodies in patients treated with interferon-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900701-7

Infliximab in Crohn's disease: first anniversary clinical experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900701-7

Clinical experience with infliximab therapy in 100 patients with Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900701-7

Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900701-7

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900701-7

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900701-7

Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900701-7

Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900701-7

Range of antinuclear antibodies in "healthy" individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900701-7

An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900701-7

Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900701-7

Recent developments in the understanding of antinuclear autoantibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900701-7

What triggers anti-dsDNA antibodies?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900701-7

A gender gap in autoimmunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900701-7

10.1016/S0016-5085(03)00701-7

7 January 2021

Identifiers

DOI

1 reference

5 February 2018

1 reference

5 February 2018